1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Exelixis’s Cabometyx Two-For-Two In A Week As Neuroendocrine Tumor Study Hits Endpoint

 
• By Alaric DeArment

The announcement of the CABINET study’s success follows by days positive results for CONTACT-02 in prostate cancer, though NETs represent a smaller commercial opportunity.

Exelixis said the Phase III CABINET trial in neuroendocrine tumors met its primary endpoint • Source: Shutterstock

Exelixis, Inc. got its second bit of good news in the space of a week with positive results from a pivotal trial of Cabometyx (cabozantinib) in pancreatic and extra-pancreatic neuroendocrine tumors (NETs), following closely the announcement of success in a study of the same drug in prostate cancer. On the other hand, while the NETs indication is one of significant unmet need, it may be relatively small in terms of revenue potential.

The company announced 24 August that the data and safety monitoring board (DSMB) of the National Cancer Institute-sponsored and Alliance...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

More from R&D

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.